Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer

Published: Monday, Sep 09, 2019
Michael Duruisseaux, MD

Michael Duruisseaux, MD

Findings from a small case series of patients with lung cancer added to evidence that afatinib (Gilotrif) is a potentially effective treatment in patients with lung adenocarcinoma who have NRG1 fusions, according to a poster presentation during the 2019 World Conference on Lung Cancer.

fusion–positive NSCLC treated with afatinib is warranted to better evaluate its potential activity,” the investigators concluded in their poster.
Duruisseaux M, Laskin JJ, Tolba K, et al. Targeting NRG1-fusions in lung adenocarcinoma: afatinib as a novel potential treatment strategy. Presented at: 2019 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 7 to 10, 2019; Barcelona, Spain; Abstract P1.14-25.

<<< 2019 World Conference on Lung Cancer
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication